FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to experimental studies in oncology, and can be used in the reproduction of melanoma B16 aggressive atypical growth in mice. Method involves the melanoma malignant growth modification with chronic pain. For this purpose, 2 weeks before the tumor is transplanted, creating a chronic pain model by tying the sciatic nerves from two sides. Subsequently, subcutaneous implantation of a suspension of tumor cells of murine melanoma B16 is carried out in a physiological solution in a volume of 0.5 ml in a dilution of 1:10. Evaluation of the experimental results is carried out in 1–4 weeks after the tumor is transplanted. Method provides a change in the melanoma B16 pathogenesis in mice, leading to an early emergence of subcutaneous tumors, early metastasis, metastasis into atypical sites, and to early death of animals.
EFFECT: such an economical and affordable model can be used to find ways of malignant tumors with extensive metastasis drug treatment.
1 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR REVERSING GENETICALLY DETERMINED INHIBITION OF GROWTH OF A MALIGNANT TUMOR IN EXPERIMENT | 2019 |
|
RU2718671C1 |
METHOD OF MODIFYING THE DEVELOPMENT OF ADENOCARCINOMA EXPERIMENTALLY | 2020 |
|
RU2743960C1 |
A METHOD FOR MODELING THE PRIMARY MULTIPLE GROWTH OF MALIGNANT TUMORS WITH THE SUPPRESSION OF ONE TUMOR BY ANOTHER IN THE CONDITIONS OF PRIMARY IMMUNODEFICIENCY | 2021 |
|
RU2750127C1 |
METHOD FOR MURINE MELANOMA LYMPHATIC AND HEMATOGENOUS METASTASIS B SIMULATION FOR NONLINEAR WHITE RATS | 2016 |
|
RU2615908C1 |
METHOD FOR CREATING POLYNEOPLASIA WITH STIMULATION OF TUMOR GROWTH IN CONDITIONS OF PRIMARY IMMUNODEFICIENCY IN EXPERIMENT | 2021 |
|
RU2751930C1 |
METHOD FOR PREVENTING THE DEVELOPMENT OF MYOCARDIAL INFARCTION IN MICE WITH MELANOMA THAT DEVELOPED AGAINST THE BACKGROUND OF CHRONIC NEUROGENIC PAIN | 2022 |
|
RU2786322C1 |
METHOD OF STIMULATING CHRONIC PAIN OF MALIGNANT GROWTH IN LUNG RATS | 2018 |
|
RU2676641C1 |
METHOD FOR ENHANCING THE GROWTH OF B16/F10 MELANOMA VERSUS THE GROWTH OF B16/F10 MELANOMA WITH SELF-GRAFTING AND SLOWING THE GROWTH OF LLC (LEWIS CARCINOMA) VERSUS THE GROWTH OF LLC WITH SELF-GRAFTING IN CASE OF MULTIPLE PRIMARY MALIGNANT TUMORS AGAINST THE BACKGROUND OF PRIMARY IMMUNODEFICIENCY | 2021 |
|
RU2759487C1 |
METHOD FOR EXPERIMENTAL BIOTHERAPY OF B16/F10 MELANOMA | 2022 |
|
RU2779698C1 |
METHOD FOR SUPPRESSING THE GROWTH OF B16 MELANOMA IN LABORATORY ANIMALS | 2022 |
|
RU2784443C2 |
Authors
Dates
2018-04-16—Published
2017-04-26—Filed